The collaboration will use Telik’s proprietary drug discovery technology, Trap (target-related affinity profiling), which enables the discovery of small molecule product candidates by taking advantage of the fundamental principle that pharmaceutically active molecules work by interacting with a protein target.
Trap can identify molecules that interact selectively with a disease-related protein target by screening as few as 200 computationally selected compounds, compared to as many as two million in traditional small molecule screening.
“I am pleased to be working with Telik to use the Trap technology for the translation of important advances in the basic understanding of cancer to potential therapeutic applications to benefit cancer patients,” said Dr Stuart Aaronson, professor and chair of oncological sciences and professor of medicine at the Mount Sinai School of Medicine, and principal investigator for this Trap collaboration. “The Trap technology may accelerate this progress.”